Z01 SC 010373 (Z01) | |||
---|---|---|---|
Title | The Synergy Between Radiotherapy and Molecularly Targeted Agents | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Camphausen, Kevin | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $631,181 | Project Dates | 10/01/2001 - N/A |
Fiscal Year | 2008 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) Digestive Diseases (50.0%) Neurosciences Research (30.0%) |
Brain (15.0%) Central Nervous System - Not Including Brain (15.0%) Colon/Rectum (20.0%) Head and Neck (15.0%) Liver Cancer (20.0%) Nervous System (30.0%) Pancreas (10.0%) |
||
Research Type | |||
Localized Therapies - Discovery and Development Localized Therapies - Clinical Applications |
|||
Abstract | |||
The goal of this project is to study the interaction of radiotherapy and molecularly targeted agents. This project focuses on expanding drugs that show synergy in vitro to the in vivo setting, with the goal of translation to the clinic. In the past year we have initiated a clinical trial with a class of agents discovered in my laboratory to be potent radiation sensitizers (histone deactylase inhibitors, HDACi). We have accrued our first 9 patients. We will initiate a brain met study and a spine met study this year. |